NCT00319254 - Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Breast NeoplasmsNeoplasm Metastasis

Interventions

DRUG

SKI-606 (Bosutinib)

SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.

Trial Locations (15)

Pfizer Investigational Site, Darlinghurst

Pfizer Investigational Site, Dijon

Pfizer Investigational Site, Tampa

Pfizer Investigational Site, Sumy

Pfizer Investigational Site, Cleveland

Pfizer Investigational Site, Saint-Herblain

Pfizer Investigational Site, Dnipropetrovsk

Pfizer Investigational Site, Uzhhorod

Pfizer Investigational Site, Santa Monica

Pfizer Investigational Site, Moscow

Pfizer Investigational Site, Duarte

Pfizer Investigational Site, Pokfulam

Pfizer Investigational Site, Floriana

Pfizer Investigational Site, Lodz

Pfizer Investigational Site, Wroclaw